3,924 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,924 shares of the company's stock, valued at approximately $245,000.

Other large investors have also recently bought and sold shares of the company. Arizona State Retirement System boosted its holdings in TransMedics Group by 1.9% during the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after acquiring an additional 184 shares during the period. Envestnet Portfolio Solutions Inc. boosted its holdings in TransMedics Group by 7.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock valued at $294,000 after acquiring an additional 317 shares during the period. Park Avenue Securities LLC boosted its holdings in TransMedics Group by 3.8% during the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock valued at $548,000 after acquiring an additional 322 shares during the period. Atlas Capital Advisors Inc. bought a new stake in TransMedics Group during the fourth quarter valued at about $31,000. Finally, Alliancebernstein L.P. boosted its holdings in TransMedics Group by 1.2% during the fourth quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock valued at $2,530,000 after acquiring an additional 500 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TMDX has been the subject of a number of recent analyst reports. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Trading Down 3.5 %

Shares of NASDAQ TMDX opened at $90.19 on Tuesday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company's fifty day moving average is $74.67 and its 200-day moving average is $77.10. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of 95.95 and a beta of 2.14.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.